Logo image of AMRN

AMARIN CORP PLC -ADR (AMRN) Stock Fundamental Analysis

NASDAQ:AMRN - Nasdaq - US0231114044 - ADR - Currency: USD

10.98  -0.13 (-1.17%)

Fundamental Rating

3

Taking everything into account, AMRN scores 3 out of 10 in our fundamental rating. AMRN was compared to 561 industry peers in the Biotechnology industry. While AMRN has a great health rating, there are worries on its profitability. AMRN is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

AMRN had negative earnings in the past year.
AMRN had a negative operating cash flow in the past year.
In the past 5 years AMRN reported 4 times negative net income.
In the past 5 years AMRN reported 4 times negative operating cash flow.
AMRN Yearly Net Income VS EBIT VS OCF VS FCFAMRN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M

1.2 Ratios

AMRN has a better Return On Assets (-13.41%) than 82.53% of its industry peers.
AMRN's Return On Equity of -18.56% is amongst the best of the industry. AMRN outperforms 86.81% of its industry peers.
Industry RankSector Rank
ROA -13.41%
ROE -18.56%
ROIC N/A
ROA(3y)-10.35%
ROA(5y)-6.44%
ROE(3y)-15.13%
ROE(5y)-9.42%
ROIC(3y)N/A
ROIC(5y)N/A
AMRN Yearly ROA, ROE, ROICAMRN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400 600 800

1.3 Margins

Looking at the Gross Margin, with a value of 51.88%, AMRN is in the better half of the industry, outperforming 76.47% of the companies in the same industry.
AMRN's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for AMRN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 51.88%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-13.34%
GM growth 5Y-7.86%
AMRN Yearly Profit, Operating, Gross MarginsAMRN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

7

2. Health

2.1 Basic Checks

AMRN does not have a ROIC to compare to the WACC, probably because it is not profitable.
AMRN has more shares outstanding than it did 1 year ago.
AMRN has more shares outstanding than it did 5 years ago.
AMRN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
AMRN Yearly Shares OutstandingAMRN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
AMRN Yearly Total Debt VS Total AssetsAMRN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

An Altman-Z score of 12.36 indicates that AMRN is not in any danger for bankruptcy at the moment.
AMRN has a Altman-Z score of 12.36. This is amongst the best in the industry. AMRN outperforms 90.37% of its industry peers.
There is no outstanding debt for AMRN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 12.36
ROIC/WACCN/A
WACC7.69%
AMRN Yearly LT Debt VS Equity VS FCFAMRN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

AMRN has a Current Ratio of 3.53. This indicates that AMRN is financially healthy and has no problem in meeting its short term obligations.
AMRN has a Current ratio (3.53) which is comparable to the rest of the industry.
AMRN has a Quick Ratio of 2.55. This indicates that AMRN is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of AMRN (2.55) is worse than 68.81% of its industry peers.
Industry RankSector Rank
Current Ratio 3.53
Quick Ratio 2.55
AMRN Yearly Current Assets VS Current LiabilitesAMRN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

More info and screens

4

3. Growth

3.1 Past

AMRN shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -6.67%.
Looking at the last year, AMRN shows a very negative growth in Revenue. The Revenue has decreased by -22.85% in the last year.
The Revenue for AMRN have been decreasing by -11.86% on average. This is quite bad
EPS 1Y (TTM)-6.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-90%
Revenue 1Y (TTM)-22.85%
Revenue growth 3Y-26.81%
Revenue growth 5Y-11.86%
Sales Q2Q%-25.66%

3.2 Future

AMRN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.76% yearly.
Based on estimates for the next years, AMRN will show a very strong growth in Revenue. The Revenue will grow by 26.83% on average per year.
EPS Next Y-43.26%
EPS Next 2Y6.66%
EPS Next 3Y13.42%
EPS Next 5Y17.76%
Revenue Next Year-8.24%
Revenue Next 2Y-1.39%
Revenue Next 3Y3.1%
Revenue Next 5Y26.83%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
AMRN Yearly Revenue VS EstimatesAMRN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M 800M
AMRN Yearly EPS VS EstimatesAMRN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -2 -4 -6 -8 -10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

AMRN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AMRN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AMRN Price Earnings VS Forward Price EarningsAMRN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AMRN Per share dataAMRN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2

4.3 Compensation for Growth

AMRN's earnings are expected to grow with 13.42% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.66%
EPS Next 3Y13.42%

More info and screens

0

5. Dividend

5.1 Amount

AMRN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AMARIN CORP PLC -ADR

NASDAQ:AMRN (5/21/2025, 8:00:00 PM)

10.98

-0.13 (-1.17%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-07 2025-05-07/bmo
Earnings (Next)N/A N/A
Inst Owners18.15%
Inst Owner Change0.06%
Ins Owners1.03%
Ins Owner Change2.36%
Market Cap4.55B
Analysts42.5
Price Target13.77 (25.41%)
Short Float %N/A
Short Ratio0.38
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)7.07%
Min EPS beat(2)-30.72%
Max EPS beat(2)44.85%
EPS beat(4)2
Avg EPS beat(4)24.12%
Min EPS beat(4)-30.72%
Max EPS beat(4)100%
EPS beat(8)4
Avg EPS beat(8)22.18%
EPS beat(12)6
Avg EPS beat(12)21.14%
EPS beat(16)9
Avg EPS beat(16)25.01%
Revenue beat(2)1
Avg Revenue beat(2)25.62%
Min Revenue beat(2)-18.83%
Max Revenue beat(2)70.07%
Revenue beat(4)2
Avg Revenue beat(4)18.53%
Min Revenue beat(4)-18.83%
Max Revenue beat(4)70.07%
Revenue beat(8)5
Avg Revenue beat(8)12.74%
Revenue beat(12)8
Avg Revenue beat(12)9.56%
Revenue beat(16)8
Avg Revenue beat(16)4.53%
PT rev (1m)1250%
PT rev (3m)1250%
EPS NQ rev (1m)-7.32%
EPS NQ rev (3m)-1785.71%
EPS NY rev (1m)0%
EPS NY rev (3m)-1326.13%
Revenue NQ rev (1m)0.15%
Revenue NQ rev (3m)13.24%
Revenue NY rev (1m)-0.63%
Revenue NY rev (3m)8.91%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 21.24
P/FCF N/A
P/OCF N/A
P/B 9.6
P/tB 9.93
EV/EBITDA N/A
EPS(TTM)-2.56
EYN/A
EPS(NY)-1.9
Fwd EYN/A
FCF(TTM)-0.07
FCFYN/A
OCF(TTM)-0.07
OCFYN/A
SpS0.52
BVpS1.14
TBVpS1.11
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -13.41%
ROE -18.56%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 51.88%
FCFM N/A
ROA(3y)-10.35%
ROA(5y)-6.44%
ROE(3y)-15.13%
ROE(5y)-9.42%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-13.34%
GM growth 5Y-7.86%
F-Score3
Asset Turnover0.33
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.53
Quick Ratio 2.55
Altman-Z 12.36
F-Score3
WACC7.69%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-90%
EPS Next Y-43.26%
EPS Next 2Y6.66%
EPS Next 3Y13.42%
EPS Next 5Y17.76%
Revenue 1Y (TTM)-22.85%
Revenue growth 3Y-26.81%
Revenue growth 5Y-11.86%
Sales Q2Q%-25.66%
Revenue Next Year-8.24%
Revenue Next 2Y-1.39%
Revenue Next 3Y3.1%
Revenue Next 5Y26.83%
EBIT growth 1Y-125.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year10.67%
EBIT Next 3Y19.47%
EBIT Next 5YN/A
FCF growth 1Y65.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y65.01%
OCF growth 3YN/A
OCF growth 5YN/A